ABSTRACT
Objective To compare the clinical results of two different anterior cervical surgical treatment for multi-segmental cervical spondylotic myelopathy (≥3 segments).Methods Twenty-three patients with segmental cervical spondylotic myelopathy,10 cases were treated with anterior cervical discectomy and fusion (ACDF) as ACDF group,13 cases were treated with anterior cervical corpectomy and fusion (ACCF) as ACCF group.The operation time,operative blood loss,JOA scores,neurological improvement rate and the variable of the D value were compared.Results The operation time and operative blood loss in ACDF group was significantly lower than that in ACCF group [(130.0 ±31.5) min vs.(150.0 ±42.5) min,(150.0 ± 120.8) ml vs.(310.0 ± 320.8) ml,P ＜ 0.05].The variable of the D value in ACDF group was significantly higher than that in ACCF group [(3.1 ± 1.4) mm vs.(2.3 ± 0.9) mm,P ＜ 0.05].There was no statistically significant difference in JOA scores,neurological improvement rate between ACDF group and ACCF group.Two cases of cerebrospinal fluid leakage in ACDF group,the oppression and drainage recovery after treatment.One case of 14 d after fistula complications in ACCF group,after patching were cured; 2 cases of titanium mesh shift,follow the fusion.Conclusions Both methods attain good clinical results.ACDF combined with ACCF treatment of multi-segmental cervical spondylotic myelopathy,with shorter operation time,relatively less blood loss,and better restoration of cervical sagittal alignment.
ABSTRACT
Objective To assess the feasibility of using biodegradable poly (lactic-co-glycolic acid) (PLGA) scaffold with controlled release of rhBMP-2 and its effect on the osteogenic activity of MSCs in vitro. Methods The PLGA scaffolds with rhBMP-2 sustained release system were made by combination of porogen-leaching and freeze-drying. The drug release kinetics was measured by enzyme-linked immunosorbent assay (ELISA) in vitro. MSCs were isolated from the bone marrow of human and cultured for 3 passages. Then, MSCs were seeded onto PLGA scaffolds. PLGA scaffolds without rhBMP-2 were used as experimental controls . Scanning electron microscopy(SEM) was used to observe the morphology of MSCs. The cell proliferation was determined by MTT assay. Results The rhBMP-2 was encapsulated into PLGA scaffolds and it was found to be continuously released from the scaffolds. The scaffolds have evident enhancing effect on ectopia osteogenesis. Conclusion PLGA scaffold containing rhBMP-2 is a new promising tissue engineering scaffold.
ABSTRACT
With the development of modem tumor diagnostic techniques and therapies, the survival rate of malignant tumor has been remarkably increased. With the increase in survival rate of cancer-beating patients, the chance of tumor metastasis is elevated. Minimally invasive treatment provides a new strategy to the therapy of spinal metastatic carcinoma. Its benefits include smaller surgical wound,, higher efficacy and fewer complications, and thus have a broad application prospects in the field of spinal metastatic tumors. In this article, a general re-view is given on minimally invasive treatments of spinal metastatic carcinoma, as well as the latest progress in the field. It was proposed that the united application of the treatment might be a promising hot spot of tumor therapy.
ABSTRACT
Objective To explore the clinical therapeutic effects in arterial interventional therapy in early osteosarcoma patients.Methods Thirty-eight early osteosarcoma patients received arterial chemoembolization therapies and performed operations.94.7% patients received limb salvage surgeries.Levels of alkaline phosphatase were tested in preoperative and postoperative phases.Results Levels of postoperativealkaline phosphatase[average(191.7±107.0)U/L]were significantly decreased compared with that before interventional therapy[average(1129.1±572.3)U/J.The survival rate in follow-up at 1,3 and 5 years Was97%,79%,50% respectively.The rate of recurrence and metastasis WAg 24%.Conclusions Arterialchemoembolization therapies in patients with early osteosarcoma could improve clinical symptoms effectively,enhance survival rate,relieve recurrence and metastasis,remain affected extremity.The clinical thempeutic effects of iodinated oil were the best among the three embolism materials.
ABSTRACT
Abstract Poly-l-lactide/beta-tricalcium phosphate (PLLA/betaTCP) composite was obtained by combining ground beta-TCP with PLLA, and absorbable rods were prepared by injection moulding. Degradations of the rods were investigated by scanning electron microscope (SEM), mass loss, molecular weight and bending strength changes. At the beginning of in vivo degradation of the rods, the molecular weight of PLLA decreases sharply with the less mass losses of the rods. As in vivo degradation progress, the surfaces of the rods changed roughly, while micropores and fine groove were observed in the inner part of the rods. The bending strength of composite rods decreased from 151 MPa to 106 MPa after in vivo degradation of 12 weeks. Tissue test reveal that PLLA/beta-TCP composite has good tissue compatibility compared with PLLA.
Subject(s)
Animals , Rabbits , Absorbable Implants , Biocompatible Materials , Chemistry , Calcium Phosphates , Chemistry , Fractures, Bone , Therapeutics , Internal Fixators , Lactic Acid , Chemistry , Materials Testing , Polyesters , Polymers , ChemistryABSTRACT
Poly lactic-co-glycolic acid (PLGA) has been attracting increasing attention in the field of bone tissue engineering because it is a biodegradable polymer with excellent biocompatibility, controllable aperture and porous rate, and a degradation rate which is suitable for bone regeneration, and moreover a suitable carrier for the sustained release of growth factors. This article reviewed the recent research progress in PLGA as a material for controlled drug delivery with emphasis on how to make the scaffold more suitable for the regeneration of the bone and which is the better way to apply sustained release of growth factors embedded in the material in bone tissue engineering. It pointed out that PLGA carrying different growth factors will become the focal point in the field of bone tissue-engineering.